Table 2.
Main International Recommendations on Venesection Therapy in HFE Haemochromatosis (with Permission from Powell,2016)34,38,39,40
| Initial Therapy | Phlebotomy | Endpoint | Maintenance Therapy | |
|---|---|---|---|---|
| Criteria for Testing | Goal | |||
| France (2005) | SF>300 µ/L in men; SF>200 µ/L in women |
5–7 mL/kg (<550 mL) once a week | SF <50 µg/L | SF <50 µg/L |
| Netherlands (2007) | Not Precise | 500 mL once a week | SF <300 µg/L | SF within the reference values |
| EASL (2010) | SF above the normal range | 400–500 mL every 1 or 2 weeks | SF <300 µg/L | SF <50 µg/L |
| AASLD (2011) | Increased SF with or without clinical symptoms | 500 mL once or twice a week | SF 50–100 µg/L | SF 50–100 µg/L |
Abbreviations: EASL, European Association for the Study of the Liver; ASSLD, American Association for the Study of Liver Diseases; SF, serum ferritin.